Contributions
Abstract: EP1615
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Background: Natalizumab (NTZ) is a humanized monoclonal antibody anti-leukocyte α4 subunit of the integrins α4β1 and α4β7, which are expressed in the cell membranes of activated T- and B-lymphocytes. Consequently, the administration of NTZ inhibits the transmigration of auto-reactive lymphocytes into the central nervous system in patients with multiple sclerosis (MS). Since this antibody remains in the peripheral blood for days or months, studies demonstrating its possible immunomodulatory effects are necessary.
Objectives: To investigate whether NTZ treatment alters the immunomodulatory molecules on the surface of plasmacytoid dendritic cells and modifies the levels of neurofilaments in the CSF of MS patients.
Methods: Blood samples from patients with multiple sclerosis under NTZ treatment and from healthy donors were collected. CSF samples were obtained from patients under NTZ therapy. Serum and PBMCs were separated to perform flow cytometry and ELISA techniques.
Results: Plasmacytoid dendritic cells from patients treated with NTZ expressed increased levels of HLA-G, PD-L1 (CD274) and CCR7 and normal levels of HLA-DR in the peripheral blood, and pDCs expressing these molecules were also present in the cerebrospinal fluid. Moreover, the level of neurofilament light (Nfl) was normal in the CSF of these MS patients compared to those of healthy controls and untreated MS patients.
Conclusion: Our results demonstrated that, in addition to the property of inhibiting the migration of lymphocytes into the central nervous system, circulating NTZ exerts an important down-regulatory effect on inflammatory responses within the CNS, which is associated with decreased neurodegeneration, as demonstrated by normal levels of Nfl.
Disclosure: Financial support: FAPESP, CNPq, CAPES
LMBS has received speaking honoraria from Biogen
Abstract: EP1615
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Background: Natalizumab (NTZ) is a humanized monoclonal antibody anti-leukocyte α4 subunit of the integrins α4β1 and α4β7, which are expressed in the cell membranes of activated T- and B-lymphocytes. Consequently, the administration of NTZ inhibits the transmigration of auto-reactive lymphocytes into the central nervous system in patients with multiple sclerosis (MS). Since this antibody remains in the peripheral blood for days or months, studies demonstrating its possible immunomodulatory effects are necessary.
Objectives: To investigate whether NTZ treatment alters the immunomodulatory molecules on the surface of plasmacytoid dendritic cells and modifies the levels of neurofilaments in the CSF of MS patients.
Methods: Blood samples from patients with multiple sclerosis under NTZ treatment and from healthy donors were collected. CSF samples were obtained from patients under NTZ therapy. Serum and PBMCs were separated to perform flow cytometry and ELISA techniques.
Results: Plasmacytoid dendritic cells from patients treated with NTZ expressed increased levels of HLA-G, PD-L1 (CD274) and CCR7 and normal levels of HLA-DR in the peripheral blood, and pDCs expressing these molecules were also present in the cerebrospinal fluid. Moreover, the level of neurofilament light (Nfl) was normal in the CSF of these MS patients compared to those of healthy controls and untreated MS patients.
Conclusion: Our results demonstrated that, in addition to the property of inhibiting the migration of lymphocytes into the central nervous system, circulating NTZ exerts an important down-regulatory effect on inflammatory responses within the CNS, which is associated with decreased neurodegeneration, as demonstrated by normal levels of Nfl.
Disclosure: Financial support: FAPESP, CNPq, CAPES
LMBS has received speaking honoraria from Biogen